130 related articles for article (PubMed ID: 32887121)
1. Sample preparation techniques for protein binding measurement in radiopharmaceutical approaches: A short review.
Moein MM; Halldin C
Talanta; 2020 Nov; 219():121220. PubMed ID: 32887121
[TBL] [Abstract][Full Text] [Related]
2. Determination of plasma protein binding of positron emission tomography radioligands by high-performance frontal analysis.
Amini N; Nakao R; Schou M; Halldin C
J Pharm Biomed Anal; 2014 Sep; 98():140-3. PubMed ID: 24922085
[TBL] [Abstract][Full Text] [Related]
3. Binding properties of the cerebral alpha4beta2 nicotinic acetylcholine receptor ligand 2-[18F]fluoro-A-85380 to plasma proteins.
Sorger D; Becker GA; Hauber K; Schildan A; Patt M; Birkenmeier G; Otto A; Meyer P; Kluge M; Schliebs R; Sabri O
Nucl Med Biol; 2006 Oct; 33(7):899-906. PubMed ID: 17045170
[TBL] [Abstract][Full Text] [Related]
4. Synthesis, Radiolabeling, and Characterization of Plasma Protein-Binding Ligands: Potential Tools for Modulation of the Pharmacokinetic Properties of (Radio)Pharmaceuticals.
Müller C; Farkas R; Borgna F; Schmid RM; Benešová M; Schibli R
Bioconjug Chem; 2017 Sep; 28(9):2372-2383. PubMed ID: 28898054
[TBL] [Abstract][Full Text] [Related]
5. Development of radioligands for in vivo imaging of type 1 cannabinoid receptors (CB1) in human brain.
Horti AG; Van Laere K
Curr Pharm Des; 2008; 14(31):3363-83. PubMed ID: 19075713
[TBL] [Abstract][Full Text] [Related]
6. In Vivo Labeling of Plasma Proteins for Imaging of Enhanced Vascular Permeability in the Lungs.
Schniering J; Borgna F; Siwowska K; Benešová M; Cohrs S; Hasler R; van der Meulen NP; Maurer B; Schibli R; Müller C
Mol Pharm; 2018 Nov; 15(11):4995-5004. PubMed ID: 30265552
[TBL] [Abstract][Full Text] [Related]
7. Candidate PET Radioligand Development for Neurofibrillary Tangles: Two Distinct Radioligand Binding Sites Identified in Postmortem Alzheimer's Disease Brain.
Cai L; Qu B; Hurtle BT; Dadiboyena S; Diaz-Arrastia R; Pike VW
ACS Chem Neurosci; 2016 Jul; 7(7):897-911. PubMed ID: 27171905
[TBL] [Abstract][Full Text] [Related]
8. Improved radiometabolite analysis procedure for positron emission tomography (PET) radioligands using a monolithic column coupled with direct injection micellar/high submicellar liquid chromatography.
Nakao R; Halldin C
Talanta; 2013 Sep; 113():130-4. PubMed ID: 23708634
[TBL] [Abstract][Full Text] [Related]
9. Application of chiral chromatography in radiopharmaceutical fields: A review.
Moein MM; Tran TA
J Chromatogr A; 2020 Nov; 1632():461611. PubMed ID: 33086153
[TBL] [Abstract][Full Text] [Related]
10. Development of radioligands for imaging of brain norepinephrine transporters in vivo with positron emission tomography.
Schou M; Pike VW; Halldin C
Curr Top Med Chem; 2007; 7(18):1806-16. PubMed ID: 17979789
[TBL] [Abstract][Full Text] [Related]
11. Subtype-selective dopamine receptor radioligands for PET imaging: current status and recent developments.
Banerjee A; Prante O
Curr Med Chem; 2012; 19(23):3957-66. PubMed ID: 22780960
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of [O-methyl-11C]RS-15385-197 as a positron emission tomography radioligand for central alpha2-adrenoceptors.
Hume SP; Hirani E; Opacka-Juffry J; Osman S; Myers R; Gunn RN; McCarron JA; Clark RD; Melichar J; Nutt DJ; Pike VW
Eur J Nucl Med; 2000 May; 27(5):475-84. PubMed ID: 10853800
[TBL] [Abstract][Full Text] [Related]
13. Approaches to measure protein binding of enzymatically unstable compounds in plasma.
Ye Z; Gao H
Bioanalysis; 2018 Apr; 10(7):451-459. PubMed ID: 29633861
[TBL] [Abstract][Full Text] [Related]
14. Radiotracer properties determined by high performance liquid chromatography: a potential tool for brain radiotracer discovery.
Tavares AA; Lewsey J; Dewar D; Pimlott SL
Nucl Med Biol; 2012 Jan; 39(1):127-35. PubMed ID: 21958855
[TBL] [Abstract][Full Text] [Related]
15. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
16. Validation of a rapid equilibrium dialysis approach for the measurement of plasma protein binding.
Waters NJ; Jones R; Williams G; Sohal B
J Pharm Sci; 2008 Oct; 97(10):4586-95. PubMed ID: 18300299
[TBL] [Abstract][Full Text] [Related]
17. Radiosynthesis and in vivo evaluation of novel radioligands for PET imaging of cerebral 5-HT7 receptors.
Hansen HD; Herth MM; Ettrup A; Andersen VL; Lehel S; Dyssegaard A; Kristensen JL; Knudsen GM
J Nucl Med; 2014 Apr; 55(4):640-6. PubMed ID: 24566002
[TBL] [Abstract][Full Text] [Related]
18. N,N-dimethyl-2-(2-amino-4-(18)F-fluorophenylthio)-benzylamine (4-(18)F-ADAM): an improved PET radioligand for serotonin transporters.
Shiue GG; Choi SR; Fang P; Hou C; Acton PD; Cardi C; Saffer JR; Greenberg JH; Karp JS; Kung HF; Shiue CY
J Nucl Med; 2003 Dec; 44(12):1890-7. PubMed ID: 14660713
[TBL] [Abstract][Full Text] [Related]
19. A simplified radiometabolite analysis procedure for PET radioligands using a solid phase extraction with micellar medium.
Nakao R; Halldin C
Nucl Med Biol; 2013 Jul; 40(5):658-63. PubMed ID: 23602762
[TBL] [Abstract][Full Text] [Related]
20. Positron emission tomography imaging in evaluation of MS pathology in vivo.
Högel H; Rissanen E; Vuorimaa A; Airas L
Mult Scler; 2018 Oct; 24(11):1399-1412. PubMed ID: 30091657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
